Clareo Health | Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA)
Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fundación Andaluza de Reumatología
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients of both sexes ≥ 18 years.
Patients diagnosed with RA (according to the American College of Rheumatology (ACR) 2010 criteria) between January 2008 and December 2012 and who have initiated treatment with at least one synthetic DMARD during that period.
Patients who have given written informed consent for their data to be collected and reviewed.
You may not be if
Patients who are already participating in a clinical trial/s at the moment of participation in this study.
Patients with whom it is suspected there will be insufficient information to complete the study objectives.
